SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 3rd, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 3rd, 2022 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 3, 2022 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). For the avoidance of doubt, to the extent that only one Investor is identified on Exhibit A attached hereto, the term Investors as used herein shall refer only to the Investor identified on Exhibit A attached hereto.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 3rd, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 3rd, 2022 Company Industry JurisdictionThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 3, 2022 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of March 3, 2022 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.